Spiromustine(Spiromustine) - 药物靶点：DNA_专利_临床

概要

基本信息

药物类型

小分子化药

别名

SHM、Spiromustine (USAN/INN)、NSC-172112

+ [1]

靶点

DNA

作用方式

抑制剂

作用机制

DNA抑制剂(DNA抑制剂)、DNA烷化剂

治疗领域

肿瘤

在研适应症-

非在研适应症

肿瘤

原研机构

National Cancer Institute

在研机构-

非在研机构

National Cancer InstituteShire Pharmaceuticals Services Ltd.

权益机构-

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C14H23Cl2N3O2

InChIKeyQNKJFXARIMSDBR-UHFFFAOYSA-N

CAS号56605-16-4

关联

100 项与 Spiromustine 相关的临床结果

登录后查看更多信息

100 项与 Spiromustine 相关的转化医学

登录后查看更多信息

100 项与 Spiromustine 相关的专利（医药）

登录后查看更多信息

60

项与 Spiromustine 相关的文献（医药）

2026-02-01·JOURNAL OF PHARMACEUTICAL SCIENCES

New method for adsorbing the pharmaceuticals on mesoporous silica: Adsorption behavior of ibuprofen on mesoporous silica via the sealed and heating method

Article

作者: Oba, Takuma ; Hanawa, Takehisa ; Ozawa, Chihiro ; Kawano, Yayoi ; Nomura, Kazuya ; Natori, Nobuyuki ; Hirose, Kaoru

Many active pharmaceutical ingredients (APIs) currently being developed are poorly soluble in water, which enhances their solubility and bioavailability critical challenges. The evaporation/condensation (EV) method, wherein crystalline APIs are dissolved in organic solvents and adsorbed onto porous materials, is used to improve the solubility of APIs. However, the use of residual organic solvents during evaporation is challenging. Recently, the sealed heating (SH) method, in which a mixture of porous materials and a sublimated API is heated in a sealed container, has been reported as an alternative to the EV method. This study focuses on mesoporous silica (MPS-4R or -2R) as a porous material. The SH method was used to investigate the adsorption of ibuprofen (IBU) on MPSs. In the PXRD study, the IBU crystals were amorphized using the SH method. The elution rate of SH mixture containing 10 wt% IBU was approximately 2.7 times higher than that of the IBU crystals at 10 min after the start of the test. Based on these results, the SH method is a novel approach for amorphizing and enhancing the solubility of poorly water-soluble drugs without the use of organic solvents.

2023-02-01·Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

Assessing growth of infants with chylothorax receiving fortified skimmed human breast milk

Article

作者: Clark, Brittani ; Nghiem‐Rao, T. Hang ; Feuling, Mary Beth ; Uhing, Michael ; Goday, Praveen ; Polzin, Elizabeth ; Karls, Catherine ; Froh, Melissa ; Handler, Stephanie S.

Abstract:

Learning Outcome:

To learn how skimmed human milk (SHM) can be used in infants with chylothorax to support adequate weight gain and nutrition while receiving human milk.

Background:

Traditional nutrition management for chylothorax is to limit long‐chain triglycerides (LCTs) and provide a diet high in medium‐chain triglycerides (MCTs). Transition from human milk to formula has been required to provide the ratio of MCT to LCT required to stop the accumulation of chyle. Although SHM may provide the right fat content for a baby with chylothorax, previous studies have shown slow growth in infants receiving SHM.

Objective:

To demonstrate that infants receiving SHM fortified with high‐MCT infant formula will have age appropriate growth without re‐accumulation of chyle.

Design/Methods:

Between 2017 and 2019, term infants with the diagnosis of chylothorax who were previously receiving human milk and transitioned to fortified SHM were monitored for growth and reaccumulation of chyle.

Results:

The six infants who were prescribed fortified SHM with high‐MCT infant formula using standardized recipes did not show reaccumulation of chyle and showed positive weight gain in five of the six study patients. The infants gained a mean weight of 30.5 g/day (±19.5), and their weight z scores improved by a mean of +0.29 (±0.33).

Conclusions:

Fortified SHM is a safe treatment option that can provide adequate nutrition for the infant with chylothorax to gain weight appropriately for age.

2023-01-01·Frontiers in neuroscience

Cerebrolysin and repetitive transcranial magnetic stimulation (rTMS) in patients with traumatic brain injury: a three-arm randomized trial.

Article

作者: Chira, Diana ; Jemna, Nicoleta ; Muresanu, Ioana ; Radu, Constantin ; Vadan, Iulia ; Muresanu, Dafin ; Hapca, Elian ; Benedek, Irina ; Strilciuc, Stefan ; Cherecheş, Răzvan ; Verisezan Rosu, Olivia

Introduction:

Traumatic brain injury (TBI) is a major public health problem affecting millions worldwide. Despite significant advances in medical care, there are limited effective interventions for improving cognitive and functional outcomes in TBI patients.

Methods:

This randomized controlled trial investigated the safety and efficacy of combining repetitive transcranial magnetic stimulation (rTMS) and Cerebrolysin in improving cognitive and functional outcomes in TBI patients. Ninety-three patients with TBI were randomized to receive either Cerebrolysin and rTMS (CRB + rTMS), Cerebrolysin and sham stimulation (CRB + SHM), or placebo and sham stimulation (PLC + SHM). The primary outcome measures were the composite cognitive outcome scores at 3 and 6 months after TBI. Safety and tolerability were also assessed.

Results:

The study results demonstrated that the combined intervention of rTMS and Cerebrolysin was safe and well-tolerated by patients with TBI. Although no statistically significant differences were observed in the primary outcome measures, the descriptive trends in the study support existing literature on the efficacy and safety of rTMS and Cerebrolysin.

Discussion:

The findings of this study suggest that rTMS and Cerebrolysin may be effective interventions for improving cognitive and functional outcomes in TBI patients. However, limitations of the study, such as the small sample size and exclusion of specific patient populations, should be considered when interpreting the results. This study provides preliminary evidence for the safety and potential efficacy of combining rTMS and Cerebrolysin in improving cognitive and functional outcomes in TBI patients. The study highlights the importance of multidisciplinary approaches in TBI rehabilitation and the potential for combining neuropsychological measurements and interventions to optimize patient outcomes.

Conclusion:

Further research is needed to establish these findings' generalizability and identify the optimal dosages and treatment protocols for rTMS and Cerebrolysin.

100 项与 Spiromustine 相关的药物交易

登录后查看更多信息